Johnson & Johnson (JNJ) Stock

It's important to assess a company's financial health before investing in its stock for dividend income. If the company is not in good financial shape, its dividends may not be sustainable.

If it gets the green light, JNJ's Tremfya will be the first IL-23 inhibitor that allows patients to choose between subcutaneous or intravenous administration for the initial treatment of ulcerative colitis.

Here are two strong dividend stocks you can invest in right now with $500. These stocks are considered reliable and have a good track record of paying dividends. Investing in them could be a smart choice for your portfolio.

Lately, users of Zacks.com have been focusing on Johnson & Johnson (JNJ). This interest prompts a closer look at what the stock might offer.

Over 90 presentations of clinical trial and real-world data showcase important evidence that could change medical practices and demonstrate a commitment to developing new treatments for patients with blood cancers. Johnson & Johnson announced that these abstracts will be shared at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, taking place from December 7-10.

On Monday, Johnson & Johnson announced that their medication for a specific skin condition achieved its primary objectives in a late-stage trial.

ICONIC-LEAD met its main goals, with 74% of patients showing clear or nearly clear skin by week 24. Meanwhile, ICONIC-TOTAL also reached its primary goal of an IGA score of 0 or 1 at week 16 for patients with hard-to-treat plaque psoriasis. Protagonist Therapeutics has received a $165 million milestone payment as part of their agreement with Johnson & Johnson for these successful studies.

Johnson & Johnson (NYSE:JNJ) will be participating in the Stifel 2024 Healthcare Conference on November 18, 2024, at 10:55 AM ET. Michael Bodner, the Group President of Heart Recovery and Circulatory Restoration, will represent the company. Rick Wise from Stifel is hosting the event and is excited to welcome J&J.

The CHMP's recommendation relies on data from advanced studies, indicating that JNJ's combination medication lowers the chance of disease worsening or death by 30% in specific patients with NSCLC.